Deleted Tweets From Scott Gottlieb, R-D.C.

Enjoy the summer – and protect yourselves and your loved ones from sun damage. #FDA is continuing to take actions to ensure that the products you use are safe and effective. https://t.co/RvJCyfNYI2 https://t.co/jFFt6rW7dD

RT @SGottliebFDA: We’ll soon release a framework similar to the Regenerative Medicine framework that’ll explain how we intend to addr… https://t.co/bsK7zSv8xf

#FDA hosting workshop to discuss draft of the Accreditation Scheme for Conformity Assessment pilot and obtain critical stakeholder input. Looking forward to working with our stakeholders to improve conformity assessment in medical device premarket reviews

RT @FDAenEspanol: Disfruta el verano y protégete a ti mismo y a tus seres queridos del daño del sol. La #FDA continúa tomando medidas para… QT @SGottliebFDA: Enjoy the summer – and protect yourselves and your loved ones from sun damage. #FDA is continuing to take actions t… https://t.co/vqQ18MBpT2)

#FDA continues to encourage adoption of biosimilars as low-cost options for patients. Today we expanded our education campaign with more resources for providers https://t.co/cdqbSmEaRi

Biosimilars hold promise to lower the cost of treatment for patients. More efforts are underway by #FDA to increase awareness about the benefits of these products https://t.co/cdqbSmEaRi

In addition to our letters to firms making these products, we urge parents, caregivers, retailers to heed our warnings, not use OTC products containing benzocaine for teething pain. We’ll also continue working with Congress to modernize our OTC drug monog

RT @AP_FDAwriter: FDA warns parents about the risks of some teething remedies; wants them off pharmacy shelves: https://t.co/Nn0lCGqdYW

Because of lack of efficacy for teething & serious safety concerns we’ve seen with OTC benzocaine oral products; FDA is taking steps to stop use of these products in young children, raise awareness of risks associated with other uses of benzocaine pro

#FDA takes steps to modernize guidance on the development of new drugs for the prevention of inhalational anthrax, reaffirming agency’s enduring commitment to the development of a full suite of medical countermeasures https://t.co/321p4wU4Eu

As part of a longstanding program encouraging the development of medical countermeasures; new #FDA policy issued today promotes innovation to thwart inhalational anthrax: https://t.co/321p4wU4Eu

RT @FDAJobs: “Our people are the agency’s most important asset. We need to invest in our approach to how we hire and retain our… https://t.co/jbq7TBxIVk

#FDA final guidance issued today is the result of a multi-year effort to advance its policy framework for the development of inhalational anthrax treatments, will help product developers design studies to appropriately establish safety/effectiveness: http

One step to curbing opioid addiction/abuse is cracking down on illicit drug internet traffic. That’s why I invited representatives from internet stakeholders, government entities, academic researchers, advocacy groups to #FDA’s Online Opioid Summit June 2

#FDA is taking action to discontinue OTC oral health products containing benzocaine intended for teething and add warnings about serious risk associated with other benzocaine oral health products https://t.co/ZhSx768a2u

Opioid addiction/abuse is an immense public health crisis, one of #FDA’s highest priorities. According to @nabp when searching online for opioids across the 3 major search engines, 91% of the 1st search results led users to an illegal online drug seller:

#FDA research helps make generic drug development and review more efficient, leading to more competition that can bring down drug costs. Join us tomorrow for our regulatory science workshop on this important topic: https://t.co/akCyuIiNT9

RT @FDA_MCMi: In case you missed yesterday's anthrax guidance announcement. Learn more about FDA's Medical Countermeasures Initiative and s… QT @SGottliebFDA: #FDA takes steps to modernize guidance on the development of new drugs for the prevention of inhalational anthrax,… https://t.co/FpC603HNEB)

June 27 #FDA Online Opioid Summit will address research depicting the ease with which illicit opioids can be found online, industry approaches to addressing this criminal activity, identifying gaps/new solutions. For information on attending or viewing: h

#FDA is taking action to discontinue OTC oral health products containing benzocaine intended for teething and add warnings about serious risk associated with other benzocaine oral health products https://t.co/2cihjElJTp

Enjoy the summer – and protect yourselves and your loved ones from sun damage. #FDA is continuing to take actions to ensure that the products you use are safe and effective. https://t.co/RvJCyfNYI2 https://t.co/jFFt6rW7dD

RT @SGottliebFDA: We’ll soon release a framework similar to the Regenerative Medicine framework that’ll explain how we intend to addr… https://t.co/bsK7zSv8xf

#FDA hosting workshop to discuss draft of the Accreditation Scheme for Conformity Assessment pilot and obtain critical stakeholder input. Looking forward to working with our stakeholders to improve conformity assessment in medical device premarket reviews

RT @FDAenEspanol: Disfruta el verano y protégete a ti mismo y a tus seres queridos del daño del sol. La #FDA continúa tomando medidas para… QT @SGottliebFDA: Enjoy the summer – and protect yourselves and your loved ones from sun damage. #FDA is continuing to take actions t… https://t.co/vqQ18MBpT2)

#FDA continues to encourage adoption of biosimilars as low-cost options for patients. Today we expanded our education campaign with more resources for providers https://t.co/cdqbSmEaRi

Biosimilars hold promise to lower the cost of treatment for patients. More efforts are underway by #FDA to increase awareness about the benefits of these products https://t.co/cdqbSmEaRi

In addition to our letters to firms making these products, we urge parents, caregivers, retailers to heed our warnings, not use OTC products containing benzocaine for teething pain. We’ll also continue working with Congress to modernize our OTC drug monog

RT @AP_FDAwriter: FDA warns parents about the risks of some teething remedies; wants them off pharmacy shelves: https://t.co/Nn0lCGqdYW

Because of lack of efficacy for teething & serious safety concerns we’ve seen with OTC benzocaine oral products; FDA is taking steps to stop use of these products in young children, raise awareness of risks associated with other uses of benzocaine pro

#FDA takes steps to modernize guidance on the development of new drugs for the prevention of inhalational anthrax, reaffirming agency’s enduring commitment to the development of a full suite of medical countermeasures https://t.co/321p4wU4Eu

As part of a longstanding program encouraging the development of medical countermeasures; new #FDA policy issued today promotes innovation to thwart inhalational anthrax: https://t.co/321p4wU4Eu

RT @FDAJobs: “Our people are the agency’s most important asset. We need to invest in our approach to how we hire and retain our… https://t.co/jbq7TBxIVk

#FDA final guidance issued today is the result of a multi-year effort to advance its policy framework for the development of inhalational anthrax treatments, will help product developers design studies to appropriately establish safety/effectiveness: http

One step to curbing opioid addiction/abuse is cracking down on illicit drug internet traffic. That’s why I invited representatives from internet stakeholders, government entities, academic researchers, advocacy groups to #FDA’s Online Opioid Summit June 2

#FDA is taking action to discontinue OTC oral health products containing benzocaine intended for teething and add warnings about serious risk associated with other benzocaine oral health products https://t.co/ZhSx768a2u

Opioid addiction/abuse is an immense public health crisis, one of #FDA’s highest priorities. According to @nabp when searching online for opioids across the 3 major search engines, 91% of the 1st search results led users to an illegal online drug seller:

#FDA research helps make generic drug development and review more efficient, leading to more competition that can bring down drug costs. Join us tomorrow for our regulatory science workshop on this important topic: https://t.co/akCyuIiNT9

RT @FDA_MCMi: In case you missed yesterday's anthrax guidance announcement. Learn more about FDA's Medical Countermeasures Initiative and s… QT @SGottliebFDA: #FDA takes steps to modernize guidance on the development of new drugs for the prevention of inhalational anthrax,… https://t.co/FpC603HNEB)

June 27 #FDA Online Opioid Summit will address research depicting the ease with which illicit opioids can be found online, industry approaches to addressing this criminal activity, identifying gaps/new solutions. For information on attending or viewing: h

#FDA is taking action to discontinue OTC oral health products containing benzocaine intended for teething and add warnings about serious risk associated with other benzocaine oral health products https://t.co/2cihjElJTp